key: cord-0718268-dv5jleao
authors: Corti, Davide; Purcell, Lisa A.; Snell, Gyorgy; Veesler, David
title: Tackling COVID-19 with neutralizing monoclonal antibodies
date: 2021-05-26
journal: Cell
DOI: 10.1016/j.cell.2021.05.005
sha: 4c30a3010b136eef977b9500a6d0aab71d3887b8
doc_id: 718268
cord_uid: dv5jleao

Monoclonal antibodies (mAbs) have revolutionized the treatment of several human diseases, including cancer, autoimmunity and inflammatory conditions and represent a new frontier for the treatment of infectious diseases. In the last twenty years, innovative methods have allowed the rapid isolation of mAbs from convalescent subjects, humanized mice or libraries assembled in vitro and have proven that mAbs can be effective countermeasures against emerging pathogens. During the past year, an unprecedentedly large number of mAbs have been developed to fight COVID-19. Lessons learned from this pandemic will pave the way for the development of more mAb-based therapeutics for other infectious diseases. Here, we provide an overview of SARS-CoV-2 neutralizing mAbs, including their origin, specificity, structure, antiviral and immunological mechanisms of action, resistance to circulating variants as well as a snapshot of the clinical trials of approved or late-stage mAb therapeutics.

Lessons learned from this pandemic will pave the way for the development of more 18 mAb-based therapeutics for other infectious diseases. Here, we provide an overview of 19 SARS-CoV-2 neutralizing mAbs, including their origin, specificity, structure, antiviral 20 and immunological mechanisms of action, resistance to circulating variants as well as a 21 snapshot of the clinical trials of approved or late-stage mAb therapeutics.

Monoclonal antibodies in infectious disease 25 26

Serotherapy of infectious diseases 27

Serotherapy refers to the therapeutic transfusion of blood serum from either previous 28 human survivors of a disease or animals that have been immunized against specific 29 organisms in order to spread passive immunity. The use of serotherapy in infectious disease 30 medicine was pioneered in 1890 by von Behring and Kitasato to combat tetanus and 31 diphtheria (Behring and Kitasato, 2013 ) and led to the development of diphtheria antitoxin 32 in 1894. This product is still in use and contributed to the dramatic reduction of mortality 33 due to diphtheria many years before the advent of the diphtheria vaccine in the late 1940s. 34

Twenty years after the first use of antitoxin, convalescent serum from survivors of the 1918 35

Spanish Flu was used to treat pneumonia, showing a modest level of efficacy when 36 administered early after symptom onset (Redden, 1919) . In the following years until the 37 present day, the efficacy of convalescent plasma for the treatment of viral respiratory 38 infections was probed in several studies that have shown some evidence for a reduction in 39 mortality, especially when given early after symptom onset (Mair-Jenkins et al., 2015) . 40 However, these studies did not formally show efficacy due to the moderate risk of bias and 41 4 ebola virus disease in Central and West Africa. These two products are based on a 122 monotherapy (ansuvimab) and on a cocktail of three mAbs 123

(atoltivimab/maftivimab/odesivimab). Both have shown similar efficacy in a randomized 124 control trial whereas two other products tested in parallel failed, including one product based 125 on a cocktail of three mAbs (Zmapp) (Mulangu et al., 2019) . These results provide 126 important insights in the development of anti-infective mAbs, including: i) mAbs can be 127 used to treat severe disease and not just in a prevention setting, ii) monotherapy can be 128 successful, i.e. the use of cocktails is not the only suitable approach and iii) not all mAb-129 based products are effective, even when cocktails are used. 130

In individuals having experienced symptoms for fewer than or equal to 5 days, which would 139

imply that individuals may have already been infected for 7 days or more before the mAbs 140 were administered. Indeed, the only indication of modest efficacy was observed in 141 outpatients when a cocktail of two mAbs (CT-P27) was administered early after symptom 142 onset (no later than 48 hours), similarly to the recommended use of the approved antiviral 143

oseltamivir (Yang et al., 2019) . There is not yet evidence of efficacy of HA stem mAbs in a 144

prophylactic setting. In this regard, the most advanced program is represented by VIR-2482, 145 a half-life extended version of the previously identified MEDI8852 mAb, which recognizes 146 a conserved epitope on the HA stem shared by all 18 IAV subtypes (Kallewaard et al., 147 2016) . This study will assess VIR-2482 for immune-prophylaxis in outpatients and could be 148 pivotal for the field to investigate if stem-directed HA mAbs can be effective in prophylaxis, 149 as indirectly suggested by a serological study in humans (Ng et al., 2019) . The breadth of 150 reactivity of HA stem mAbs towards all influenza A viruses represents an opportunity to 151

develop an off-the-shelf approach to prepare for future influenza A pandemics. 152

Finally, several mAbs are under investigation to prevent or treat human 153 immunodeficiency virus 1 (HIV-1) infection. A comprehensive and updated overview is 154 provided by Nussenzweig and Barouch to reflect recent progress in the field (Caskey et al., 155 2019; Julg and Barouch, 2021) . These mAbs are broadly neutralizing and target a subset of 156 vulnerability sites on the HIV-1 Env (i.e., CD4-binding site, base of the V3 loop, MPER and 5 VRC01 did not prevent HIV-1 infection (Corey et al., 2021) . However, 75% protection was 162 observed in subjects exposed to HIV-1 isolates that were potently neutralized in vitro by 163 VRC01, suggesting that prophylaxis of HIV-1 could be achieved by using more potent 164 mAbs with broader coverage of field isolates. In a therapeutic setting, preclinical work 165

showed that in contrast to monotherapy, a combination of mAbs provided prolonged control 166 of infection (using simian-human immunodeficiency virus models in macaques) with no 167 evidence of escape. It was hypothesized that this control was mediated by T cell immunity 168 (Barouch et al., 2013; Schoofs et al., 2016) and boosted by viral antigen presentation 169 through immune complexes formed between HIV-1 envelope glycoprotein and the infused 170 mAbs, through the so-called antibody vaccinal effect. Human trials showed that 171 monotherapy only transiently controlled virus replication with the rapid emergence of 172 escape variants mirroring the results obtained with small-molecule drugs. Combination 173 therapy was far more effective than monotherapy in viremic individuals, but it did not 174 completely suppress viremia in participants with high baseline viral loads. The combination 175 of two broadly neutralizing mAbs was shown to be effective in maintaining prolonged 176 suppression after antiretroviral therapy interruption (Mendoza et al., 2018 Finally, the recent emergence of several SARS-CoV-2 variants of concern (VOC) has 227

shown limitation in the coverage by some of these mAbs which target epitopes mutating 228 open RBD state and appears to be located between site Ia/class 1 and the cryptic site II/class 4 263 site. The epitope recognized by REGN10987 mAb (located in between site Ia/class 1 and the 264 cryptic site II/class 4 site) is mostly exposed at the surface of the RBD in the closed state but 265 not accessible to the mAb due to steric hindrance with a neighboring protomer. Therefore, 266

REGN10987 requires RBD opening for mAb binding to occur. Conversely, other RBM mAbs 267

can recognize both open and closed states of the RBD (site Ib or class 2; LY-CoV555, 268 J o u r n a l P r e -p r o o f 8 AZD1061 and BGB-DXP593) (Figure 2a- combination of X-ray crystallography and/or cryo-EM analysis (Fabs shown as light blue 300 cartoons and RBD orientation fixed in the upward state shown on S trimer, left image; PDBs: 301 see Table 1 ). ACE2 and mAbs footprints shown in blue and light green, respectively. 302

Footprints on RBDs defined according to 5 Å distance from ACE2 or mAbs contacting 303 residues. The stem of N343 glycan shown as black spheres. MAbs labelled using both original Blocking of infection of target cells 324

Twelve out of the 14 mAbs presented in this review neutralize SARS-CoV-2 entry by 325 blocking engagement of ACE2 by targeting epitopes overlapping with the RBM. In some 326 cases, mAbs binding to RBM can also prematurely trigger fusogenic S conformational 327 changes that could result in the inactivation of the protein (Lempp et al., 2021) , as has also 328 been previously shown for the SARS-CoV-specific neutralizing mAb S230 (Walls et al., 329 2019). It is therefore possible that RBM mAbs may act both by blocking binding to the ACE2 330 entry receptor, but also by inactivating S by acting as receptor mimics before viral encounter 331 of a host cell. As described below this mechanism may also alter the ability of these mAbs to 332 promote effector functions. RBM mAbs can also lock the RBD conformation in the closed 333 state, thus preventing the engagement of ACE2 on target cells. open RBDs, and also to promote membrane fusion (Lempp et al., 2021) . The access to site 360

Ib/class 2 is not dependent on the opening state of the RBD although the angle of mAb 361

binding to the RBD may sterically prevent binding of other IgGs to neighboring RBDs in the 362 same S trimer, thus reducing overall occupancy. Conversely, non-ACE2 blocking mAbs 363 target highly exposed and distal sites on the RBD and are expected to have access to all three 364 epitopes on the S trimer, allowing full occupancy (i.e., 3 IgG molecules bound per S trimer) 365 on virions, but also on S displayed at the surface of infected cells. An overall high density IgG 366 binding on the surface of virions may sterically shield the engagement of ACE2 on the surface 367 of target cells (Figure 3) , thus possibly explaining the blocking of infection by S309 and 368 NTD-specific mAbs. A recent study showed that S309 effectively blocked the ACE2-369 dependent entry of SARS-CoV-2 in the presence of membrane lectins and also to inhibit the 370 fusogenic rearrangement induced by receptor mimicking RBM antibodies that leads to cell-371

to-cell fusion. Thus, non-RBM mAbs could block viral infection by sterically interfering with 372 ACE2 engagement but also by preventing structural rearrangement of the S glycoprotein that 373 is required for viral fusion (Lempp et al., 2021) . 374

Whether occupancy is relevant to viral neutralization is unclear but it might affect the 375 ability of mAbs to trigger effector functions, since the density of mAbs on virions or infected 376 cells can influence the ability to engage and activate low affinity which collectively now account for more than 90% of the currently sequenced viruses ( Figure  518 4). 519

Several mutations found in these VOC/VOI are found to reduce or abolish the 520 neutralizing activity of several mAbs, including those already approved or in late stage of 521 development (Figure 5) . Some of these VOC/VOI have also been shown to reduce 522 neutralizing titers of vaccine-elicited antibodies, possibly reducing vaccine effectiveness and 523 the duration of the protection ( Overview of COVID-19 mAbs clinical trials 592

MAbs approved for early therapy of COVID-19 593

The pandemic has revolutionized the design and speed of clinical trials, including 594 phase 1/2/3 adaptive trials that have led to approvals of therapeutic mAbs for COVID-19 in 595 record time. To date, four mAb products have been approved under an Emergency Use 596 Authorization (EUA) or conditional marketing authorization based on Phase 2 and/or Phase 3 597 interim data for COVID-19 for the same indication, i.e., early therapy in at risk individuals 598 (Figure 6 ). An overview of the performed and ongoing clinical trials for all 14 mAbs 599 described in this review is provided in Table 1 . 600

Bamlanivimab was the first COVID-19 authorized mAb (November 9, 2020) and 601 received from the FDA an EUA for the treatment of mild to moderate COVID-19 in adults 602 and pediatric patients 12 years (over 40 kg) and older with a positive COVID-19 test, who are 603 at high risk for progressing to severe COVID-19 and/or hospitalization (Chen et al., 2021a). 604

The EUA was based on interim data from the BLAZE-1 Phase 3 study in patients with 605

recently diagnosed mild to moderate COVID-19 in the outpatient setting. The approved dose 606 was 0.7 g to be administered by a single intravenous infusion within 10 days of symptom 607 onset. Two weeks later, the REGN-COV2 cocktail (casirivimab and imdevimab) also received 608

an EUA for use in the same patient population for the treatment of mild to moderate COVID-609 19 in high-risk patients at a dose of 2.4 g (1.2 g casirivimab and 1.2 g imdevimab) 610

administered as a single intravenous infusion (Weinreich et al., 2021) . In March 2021, interim 611 analysis showed a 70% reduction in hospitalization or death but no dose-dependent effect 612

(1.2, 2.4 or 8 g). In February 2021, the FDA also granted an EUA for the combined use of 613 bamlanivimab (0.7 mg) and etesevimab (1.4 g) for the same indication for which 614 bamlanivimab was approved, i.e., treatment of mild to moderate COVID-19 in at risk patients 615 (Gottlieb et al., 2021) . In addition, the EUA for this combination allowed for a much-reduced 616 infusion time of 21 minutes compared to that authorized for bamlanivimab alone (60 617 minutes). The use of these mAbs is now authorized in multiple countries. A fourth approval 618 for the same indication (i.e., early therapy in adults) occurred in early February 2021 for 619 regdanvimab by Celltrion. Regdanvimab received a conditional marketing authorization by 620

South Korea's drug safety agency. This approval was based on the first part of a global phase 621 2/3 trial showing that progression rates to severe COVID-19 were reduced by 54% for 622 patients with mild-to-moderate symptoms and 68% for patients aged 50 years and older. 623

Currently, Celltrion is seeking conditional approvals by the European Medicines Agency 624

(EMA) and FDA. 625 doses tested forced the initial use of intravenous administration due to the high volume that 631 would be required for the highest doses that would not be compatible with intramuscular or 632 subcutaneous routes. Dose sparing is also key to increase the overall number of available 633 doses for each lot of produced drug product. So far, intravenous administration has limited 634 the use of these approved mAbs since this route requires a hospital setting or access to 635 infusion centers. The shift to different routes, such as intramuscular or subcutaneous (Table  636 1), is under way and will possibly contribute to a facilitated and larger access to these mAbs. 637

Another important finding relates to primary endpoints used to measure the success of 638 these clinical trials. Virological endpoints did not always reflect clinical endpoints, and the 639 latter were ultimately the key drivers for approval. For instance, combination of 640 bamlanivimab with etesevimab or bamlanivimab monotherapy showed similar efficacy on 641 clinical endpoints, while combination therapy appeared to be more efficacious on virological 642 endpoints. It is unclear whether measuring viral replication in the upper airways with 643 molecular-based methods (i.e., RT-PCR) is an accurate measure of viral neutralization, since 644 viral RNA may persist even in the absence of replication-competent virus. In addition, viral 645 load in the lower respiratory tract would better reflect the injury response than the viral load 646 in nasopharyngeal secretions, but this type of sampling is highly invasive and overall 647 unpractical. Two factors were shown to influence the level of benefit of the mAb in the early 648 therapy setting: the immune status at baseline, i.e., seropositive vs seronegative and the viral 649 titer at baseline, i.e., high vs low. The greatest benefit from mAbs (particularly for REGN-650 COV2 mAbs) was observed for seronegative patients with a high viral load at baseline, 651

suggesting that the early development of endogenous antibodies may contribute to reduced 652 disease severity and that high viral replication is associated with higher probability of severe 653 disease outcome. 654

It is remarkable that approval was obtained in only 9-10 months from the initial 655 discovery of these mAbs. This rapid process was made possible thanks to several factors, 656

including a rapid isolation of the mAbs, an accelerated manufacturing process to generate 657 clinical grade mAbs in only 3-4 months (Kelley, 2020) , all-in-one clinical studies assessing 658 both safety and efficacy and a rapid analysis and approval by regulatory agencies. An inherent 659 limitation of this rapid development process was that these mAbs could not be characterized 660

for their resistance profile against variants that did not exist at that time. Importantly, these are the first antiviral mAbs authorized for use in a therapeutic 676 setting for respiratory pathogens, proving the concept that established respiratory infections 677

can be cured with mAbs, at least when mAbs are administered at an early stage of the disease. 678

These same approved mAbs are also under investigation in multiple clinical trials (see below) 679

to assess their efficacy in prophylaxis, post-exposure prophylaxis in residents and staff of 680 long-term care facilities as well as in late therapy, where mAbs are tested in hospitalized 681

patients with different degrees of disease severity ( Table 1 ).

MAbs tested for early therapy of COVID-19 in advanced clinical stages 684

The success of early therapy of mild to moderate COVID-19 in high-risk patients by 685 the mAbs presented above represents an important proof-of-concept that similar mAbs or 686 mAbs that may provide an optimal coverage of evolving VOC is warranted. 687

The other most advanced mAb for early therapy of COVID-19 is VIR-7831 (sotrovimab). 688 VIR-7831 is a derivative of the cross-reactive S309 mAb that was engineered for half-life 689 extension and potentially improved biodistribution in the lungs by the introduction of the LS 690 mutation in Fc. This mAb was investigated in a phase 3 study in patients with early-stage 691 COVID-19 infection, who are at high risk for hospitalization (i.e., patients ≥55y with pre-692 existing lung or cardiovascular disease) and administered as a 0.5 g dose via intravenous 693

infusion. At the time of publication, this phase 3 study has been stopped early due to 694 outstanding efficacy, i.e., 85% reduction in hospitalization or death, and an EUA application 695 for the early therapy use of VIR-7831 is currently under evaluation at the FDA. In parallel, 696

VIR-7831 is also tested in a phase 2 early therapy study in adults in combination with 697 bamlanivimab (BLAZE-4) far shown a lack of efficacy for azithromycin, convalescent plasma, and lopinavir-ritonavir. 743

The testing of REGN-COV2 in hospitalized patients receiving mechanical ventilation or high-744 flow oxygen was halted after the observation of a potential safety signal and an unfavorable 745 risk/benefit profile. However, the testing of REGN-COV2 continued for hospitalized patients 746

with less serious cases. The overall lack of efficacy of antiviral mAbs observed in 747 hospitalized patients in late stages of disease is reminiscent of what was observed with the 748 influenza HA stem mAb MHAA4549A that did not improve clinical outcomes over the 749 standard of care (i.e. oseltamivir) alone when tested as late therapy in hospitalized patients 750 (Lim et al., 2020) . 751

The efficacy of mAbs in hospitalized patients, and the understanding of which disease 752 stage would be compatible with the beneficial effect of mAbs is key to add more therapeutic 753

options to the current armamentarium of drugs to reduce severity and mortality in the 754 advanced stages of COVID-19. Importantly, the use of anti-inflammatory drugs, which can 755 limit the local damage triggered by SARS-CoV-2 infection, has also involved the use of 756 mAbs. Two approved mAbs, sarilumab and tolicizumab, directed to the receptor of the pro- an overall improvement of medical conditions was observed, while the third study did not 764 observe a beneficial effect over placebo. Several variables may have influenced the disparate 765 outcomes of these trials, including the definition of the patient population eligible for 766 enrollment. The most notable is that in the two successful studies most of the patients 767 received glucocorticoid therapy as standard of care, while only a minority of patients of the 768 COVACTA study did. These results may suggest a possible additive or synergistic effect in 769 using anti-inflammatory drugs (i.e., IL-6 and glucocorticoids) acting with different modalities. 770

These results may call for combination therapies utilizing antiviral mAbs (or small molecule 771 drugs) with anti-inflammatories designed to address immune dysregulation (e.g., tolicizumab, 772 sarilumab and glucocorticoids) with the goal to improve efficacy in hospitalized patients and 773

possibly expand the therapeutic window of intervention. 774 775

MAbs tested for prophylaxis of COVID-19 in advanced clinical development 776

In the setting of prophylaxis, mAbs could potentially be used alone or as a 777 complement to vaccines. MAbs could also be used to provide an additional layer of protection 778 for individuals at high risk of developing severe complications of COVID-19, such as the 779 elderly and individuals with comorbidities or in those who are immunocompromised, and also 780 to complement vaccine efficacy in case of significant SARS-CoV-2 antigenic drift. 781 although publication of data from either trial is still pending and data from these trials was 788 only available via press release. Bamlanivimab was reported to prevent COVID-19 in nursing 789 homes where both residents and staff who tested negative for SARS-CoV-2 were enrolled. 790

The subjects were followed for 8 weeks and treatment with mAb was reported to significantly 791 lower the frequency of symptomatic COVID-19, suggesting that subjects had up to an 80% 792 lower risk of COVID-19. Results for the REGN-COV2 cocktail was reported from 793 approximately 400 subjects who were seronegative and did not have COVID-19 at baseline, 794 but who had a household member who had COVID-19. Here, prophylaxis with the cocktail 795 was reported to prevent 100% of the symptomatic infections and had 50% lower rates of 796 infection. Although viral loads were not reported for the bamlanivimab study, the peak viral 797 loads in the placebo group of the REGN-COV2 household contact study were reported to be 798 more than 100-fold higher than those treated with mAb and treatment with REGN-COV2 was 799

shown reduce the duration of viral shedding. Both bamlanivimab and REGN-COV2 are IgG1 800 mAbs without Fc modifications and data reported for these trials only looked at subjects soon 801 after mAb administration (i.e., 2 months or less). Taken together these data indicate a high 802 potential for mAb-based immune-prophylaxis of COVID-19 and support the hypothesis that 803 protection from infection and disease can be mediated by neutralizing mAbs, and furthermore 804

indicating that vaccine-elicited antibodies are likely the major correlate of protection, as These preliminary findings represent an important proof of concept for the 808 development of mAbs with half-life extension to enable safe and reliable protection for up to 809 6-12 months that could be used as a vaccine alternative for individuals who respond poorly to 810 or are not eligible for vaccination. The combination of RBM mAbs AZD8895 and AZD1061 811 was engineered for half-life extension with the YTE mutation but also to abrogate effector 812

functions with the addition of the TM mutation in the Fc. This mAb cocktail is being tested in 813 an early therapy study, but also in a large pre-exposure prophylactic study enrolling up to 814 5,000 participants administered with a low dose of the AZD8895/AZD1061 cocktail 815 (0.15+0.15 g of each mAb) that is compatible with intramuscular delivery. A primary 816 completion date of the prophylactic trial is expected in August 2021 and will assess the 817 incidence of SARS-CoV-2 PCR positive symptomatic illness against placebo for a period up 818

to 6 months. The lack of effector functions of the AZD8895/AZD1061 cocktail and the results 819 of its efficacy may be important to determine the contribution of effector functions to efficacy 820 in prophylactic or therapeutic settings. The use of low doses such as the one used for the 821 AZD8895/AZD1061 cocktail is key for a low volume intramuscular or subcutaneous injection 822 of a high concentration product. As mentioned above the shift from intravenous to these 823 routes of administration is required for a larger access to these mAbs. 824 825

Concluding remarks and future perspectives. 826

This review provides a comprehensive and up-to-date report on a selection of neutralizing 827 mAbs against SARS-CoV-2 that have been or are being developed clinically. These mAbs 828 target multiple sites on the SARS-CoV-2 S RDB and have shown different degrees of 829 vulnerability to circulating VOC/VOI. Collectively, the data published to date suggest that 830 their efficacy in preventing or controlling SARS-CoV-2 infection in animal models rely on 831 viral neutralization, but also on other indirect mechanisms, such as effector functions. The 832 rapid successes obtained with these mAbs in both prophylactic and therapeutic clinical trials 833 has been made possible thanks to the extensive experience accumulated in the past years on 834 the swift isolation of human mAbs, on the availability of multiple Fc engineering approaches 835 aimed to fine tune effector functions and improve half-life, as well as on the great advances 836 made in the manufacturing process. In one single year, the field of anti-infective mAbs has 837 gained more knowledge regarding the clinical use of these molecules than what has been 838 accumulated in the past twenty years. Several factors still limit the successful contribution of 839 approved mAbs to the control of COVID-19 pandemic: the need for very large-scale 840 manufacturing (which could benefit from cooperation among public and private sectors), the 841 awareness that these are now available treatments among both patients and providers and the 842 need to rapidly shift to routes of administration not requiring hospital settings. The partial or 843 complete success in filling these gaps may ultimately foster the global access to mAbs to 844 reduce the overall COVID-19 morbidity and mortality. 845 846

Acknowledgements 847

We would like to thank Siro Bianchi for the help in the preparation of the figures and Julia Di 848

Julio for the analysis of prevalence of VOCs. 

Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute 868 Uncomplicated Influenza

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 874 convalescent plasma

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

A perspective on potential antibody-dependent enhancement of SARS-CoV-879 2

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an

SARS-CoV-2 neutralizing antibody structures 885 inform therapeutic strategies

SARS-CoV-2 neutralizing antibody structures inform 888 therapeutic strategies

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal 891 antibodies in SHIV-infected rhesus monkeys

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and 894 hamsters

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with 897 individual antibodies

Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-899

Fc-optimized antibodies elicit CD8 immunity 901 to viral respiratory infection

The role of IgG Fc receptors in antibody-dependent 903 enhancement

Three-quarters attack rate of SARS-CoV-2 in the 906

Brazilian Amazon during a largely unmitigated epidemic

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of 912 Convalescent Patients' B Cells

Motavizumab for prophylaxis of respiratory syncytial virus 915 in high-risk children: a noninferiority trial

Broadly neutralizing anti-HIV-1 monoclonal antibodies 917 in the clinic

The dual function monoclonal antibodies VIR-7831 and VIR-7832 920 demonstrate potent in vitro and in vivo activity against SARS-CoV-2

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single 925 supersite

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-933 derived polyclonal antibodies

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic 942 coronaviruses in mice

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

In vitro and in vivo preclinical studies predict REGEN-COV protection against 948 emergence of viral escape in humans

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 998 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

Palivizumab: where to from here? Expert Opinion on Biological

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral 1003

Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Changes in symptomatology, reinfection, and transmissibility associated with the 1006 SARS-CoV-2 variant B.1.1.7: an ecological study

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by 1009 polyclonal human plasma antibodies

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-1012

Binding Domain that Escape Antibody Recognition

Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants

A Neutralizing Monoclonal Antibody for 1018 Hospitalized Patients with Covid-19

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody

Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated 1029 influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study

Fc receptor but not complement binding is important in 1033 antibody protection against HIV

Effector function 1035 activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 1039 Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by 1042 infection and vaccination

Tocilizumab in patients admitted to hospital with COVID-19 1045 (RECOVERY): preliminary results of a randomised, controlled, open-label

Interleukin-6 Receptor Antagonists in Critically Ill 1048 Patients with Covid-19

An mRNA Vaccine against SARS-CoV-2 -1051 Preliminary Report

The neutralizing antibody, LY-CoV555, protects 1054 against SARS-CoV-2 infection in non-human primates

Human 1056 neutralizing antibodies elicited by SARS-CoV-2 infection

Broadly neutralizing antibodies for HIV-1 prevention and therapy

Structure and Function Analysis of an Antibody Recognizing 1061

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

Developing therapeutic monoclonal antibodies at pandemic pace

Process and operations strategies to enable global access to 1067 antibody therapies

SARS-CoV-2 evolution during treatment of chronic infection

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

The influenza virus hemagglutinin head 1078 evolves faster than the stalk domain

SARS-CoV-2 structure and replication characterized by in 1081 situcryo-electron tomography

Enhanced neonatal Fc receptor function improves protection against primate SHIV 1084 infection

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 1087 mRNA vaccinated individuals

CoV-2 vaccines and therapies

Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing 1092 activity of different classes of antibodies

Functional assessment of cell entry and receptor usage for SARS-1094

CoV-2 and other lineage B betacoronaviruses

The 1096 Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

A Phase 2 Randomized, Double-Blind

Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection

Neutralizing Activity of BNT162b2-Elicited Serum

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal 1105 and serum antibody neutralization

The Role of Disease Severity and Demographics in the Clinical 1108 Course of COVID-19 Patients Treated with Convalescent Plasma

The effectiveness of convalescent plasma and 1111 hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a 1112 systematic review and exploratory meta-analysis

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-1117

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Correlates of protection against SARS-CoV-2 in rhesus macaques

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-1129 elicited human sera

A Randomized, Controlled Trial of Ebola Virus 1132

Disease Therapeutics

BNT162b2 Vaccination Effectively 1134 Prevents the Rapid Rise of SARS-CoV-2 Variant B.1.1.7 in high risk populations in Israel

Novel correlates of protection against pandemic H1N1 influenza A virus 1138 infection

Statement-NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies

Structural characterization of a 1143 human Fc fragment engineered for lack of effector functions

Elucidating the interplay between IgG-Fc valency and FcgammaR 1146 activation for the design of immune complex inhibitors

Transmission of SARS-CoV-2 on mink farms 1149 between humans and mink and back to humans

Mapping Neutralizing and Immunodominant Sites on the 1152

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Broad and potent activity against SARS-like viruses by an engineered 1165 human monoclonal antibody

Treatment of Influenza-Pneumonia by Use of Convalescent Human Serum. The Boston

Convergent antibody responses to SARS-CoV-2 in convalescent 1170 individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small 1173 animal model

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Trends of mutation accumulation across global SARS-CoV-2 genomes: Implications for the evolution of the 1179 novel coronavirus

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. bioRxiv

Resurgence of COVID-19 in Manaus, Brazil, 1184 despite high seroprevalence

Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an 1187 endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations

Antibody potency, effector function, and combinations in 1191 protection and therapy for SARS-CoV-2 infection in vivo

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host 1194 immune responses against HIV-1

A human 1196 neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Suptavumab for the Prevention of Medically Attended Respiratory 1199

Syncytial Virus Infection in Preterm Infants

The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-1202 SIGN and DC-SIGN

Antibodies to the SARS-CoV-2 receptor-binding domain that 1205 maximize breadth and resistance to viral escape

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Complete map of SARS-CoV-2 RBD 1210 mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding 1214

Neutralizing and protective human monoclonal antibodies recognizing 1217 the N-terminal domain of the SARS-CoV-2 spike protein

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion 1220 glycoprotein

Sixteen novel lineages of SARS-CoV-2 in South Africa

Circulating SARS-CoV-2 spike N439K variants maintain 1226 fitness while evading antibody-mediated immunity

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via 1229 multiple mechanisms

Structural basis for broad sarbecovirus neutralization by a human monoclonal 1232 antibody

Structural insights into coronavirus entry

Convalescent plasma treatment is associated with lower mortality and 1236 better outcomes in high risk COVID-19 patients -propensity score matched case-control study

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on 1239 Transmissibility and Pathogenicity

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD 1242 spike epitopes in COVID-19 convalescent plasma

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein 1245

Nanoparticle Vaccines for SARS-CoV-2

Structure, Function, 1247 and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus 1252 Fusion

A human monoclonal antibody blocking SARS-CoV-2 1255 infection

Antibody resistance of SARS-CoV-2 variants B

mRNA vaccine-elicited antibodies to SARS-CoV-2 and 1262 circulating variants

Broad neutralization of SARS-related viruses by human monoclonal 1265 antibodies

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Escape from neutralizing antibodies by SARS-CoV-2 spike 1271 protein variants

Antibodies targeting sialyl Lewis A mediate tumor 1273 clearance through distinct effector pathways

SARS-CoV-2 501Y.V2 escapes neutralization by 1276 South African COVID-19 donor plasma

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for 1279 optimal therapeutic protection

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine -1287 Preliminary Report

In vitro characterization of five humanized OKT3 effector function 1290 variant antibodies

Phase IIb study evaluating the efficacy and safety of anti-influenza A monoclonal antibody

P27, in subjects with acute uncomplicated Influenza A Infection

A highly 1295 conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Enhanced antibody half-life improves in vivo activity

Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in 1301 cotton rats

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to 1306 neutralization by monoclonal antibodies palivizumab and/or motavizumab

A highly potent extended half-life antibody as a potential RSV 1309 vaccine surrogate for all infants

Potently neutralizing and protective human antibodies against SARS-CoV-2